Tag: Abivax
Abivax: difficult start for the biotech on the Nasdaq
(CercleFinance.com) – Abivax lost more than 14% on Friday for its first steps on the Nasdaq, reflecting both the current difficult market conditions and the recent lack of investor interest…
Abivax announces pricing of its IPO on the Nasdaq Global Market. – 10/20/2023 at 3:05 p.m.
ABIVAX press release Abivax announces pricing of its IPO on the Nasdaq Global Market. Abivax SA “Abivax” or the “Company”), a clinical-stage biotechnology company focused on the development of therapeutic…
Abivax: announces the IPO price of its securities on Nasdaq
(AOF) – Abivax today announces the pricing of its securities for its IPO on the Nasdaq Global Market. This introduction will be made through a capital increase of 20,325,500 new…
Abivax announces the IPO price of its securities on Nasdaq – 10/20/2023 at 3:17 p.m.
(AOF) – Abivax today announces the pricing of its securities for its IPO on the Nasdaq Global Market. This introduction will be made through a capital increase of 20,325,500 new…
Abivax: the price of the IPO on the Nasdaq at the bottom of the range – 10/20/2023 at 3:32 p.m.
(CercleFinance.com) – The French biotechnology company Abivax set a price of $11.60 on Friday for its IPO on the Nasdaq, at the bottom of the indicative range of $11.60-13 that…
Abivax: Difficult start for the biotech on the Nasdaq
Read also (CercleFinance.com) – Abivax lost more than 14% on Friday for its first steps on the Nasdaq, reflecting both the current difficult market conditions and the recent lack of…
Abivax: the price of the IPO on the Nasdaq at the bottom of the range
(CercleFinance.com) – The French biotechnology company Abivax set a price of $11.60 on Friday for its IPO on the Nasdaq, at the bottom of the indicative range of $11.60-13 that…
Abivax announces the resumption of trading of its ordinary shares on Euronext Paris. – 10/20/2023 at 3:50 p.m.
ABIVAX press release Abivax announces the resumption of trading of its ordinary shares on Euronext Paris. Abivax SA (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on the development…
Abivax announces the filing of an “Amendment” to the Registration Document (“FORM F-1”), including an indicative price range. – 10/19/2023 at 00:21
ABIVAX press release Abivax announces the filing of an “Amendment” to the Registration Document (“FORM F-1”), including an indicative price range. Abivax SA (“Abivax” or the “Company”), a clinical-stage biotechnology…
Abivax announces the start of roadshows as part of its Global Offering and Nasdaq listing project. – 10/16/2023 at 5:45 p.m.
ABIVAX press release Abivax announces the start of roadshows as part of its Global Offering and Nasdaq listing project. Abivax SA (“Abivax” or the “Company”), a clinical-stage biotechnology company focused…
Abivax: appointments to follow
By Claude Leguilloux Published on 06/10/2023 at 09:19 a.m. Abivax remains stable at 13 euros, while the clinical-stage biotechnology company focused on the development…
Abivax announces new results on its flagship product obefazimod – 02/10/2023 at 6:19 p.m.
(AOF) – Abivax announced today that three datasets on its lead drug candidate, obefazimod, will be presented at the United European Week of Gastroenterology (UEG) meeting, October 14-17, 2023, in…